Drugs / Survodutide
Trials 31 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 119 trials | ||||||
| Phase 1 | NCT07407348 | Mar 2026 → Jan 2027 expected | obesity disorder | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT07413913 | Mar → May 2026 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07221591 | Nov 2025 → Aug 2026 overdue | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07071974 | Jul → Oct 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06745284 | Mar 2025 → Jan 2027 expected | obesity disorder | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06772532 | Feb → May 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05202353 | Oct 2024 → Dec 2026 expected | obesity disorder | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06564441 | Oct 2024 → Dec 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06492135 | Aug 2024 → Apr 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06352411 | May 2024 → Sep 2025 | impaired renal function disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06352424 | Apr 2024 → Feb 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06200467 | Mar 2024 → Oct 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05896384 | Dec 2023 → Feb 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05751226 | Apr 2023 → Aug 2024 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05421338 | Jul → Nov 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05296733 | Apr 2022 → Dec 2023 | liver disorder, obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04384081 | Jun → Nov 2020 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03591718 | Jul 2018 → Apr 2020 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03175211 | Jun 2017 → Feb 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07206290 | Mar 2026 → Nov 2027 expected | chronic kidney disease | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04771273 | Apr 2021 → Nov 2023 | metabolic dysfunction-associated steatohepatitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04667377 | Mar 2021 → Sep 2022 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04153929 | Apr 2020 → Oct 2021 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT06632457 | Nov 2024 → Jun 2029 expected | metabolic dysfunction-associated steatohepatitis | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06632444 | Sep 2024 → Dec 2031 expected | fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06309992 | Apr 2024 → Oct 2025 | metabolic dysfunction-associated steatohepatitis, obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT06214741 | Feb 2024 → Jul 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT06176365 | Jan 2024 → Dec 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT06066528 | Nov 2023 → Dec 2025 | obesity disorder, type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT06066515 | Nov 2023 → Dec 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT06077864 | Nov 2023 → Jun 2026 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | survodutide | “The purpose of this study is to find out whether a medicine called survodutide (BI 456906) has an effect on cardiac safety.” NCT06200467 ↗17“the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906)” PMID 38095657 ↗ Dec 2023 “Formulation A of survodutide” NCT07407348 ↗ |
| Known as | BI 456906 | “Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)” NCT07407348 ↗16“the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906)” PMID 38095657 ↗ Dec 2023 “Survodutide (BI 456906)” NCT07206290 ↗ |
| Known as | Survodutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314776 ↗ |
| Action | Activate | “novel subcutaneous glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist BI 456906” PMID 36527386 ↗ Jan 20231“Glucagon-like peptide 1 receptor agonist” CHEMBL5314776 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314776 ↗ |
| Route | Subcutaneous | “novel subcutaneous glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist BI 456906” PMID 36527386 ↗ Jan 2023 |
| Target | GCGR | “BI 456906 reduced plasma amino acids and glucagon, indicating target engagement at GCGRs and GLP-1Rs.” PMID 36527386 ↗ Jan 2023 |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL5314776 ↗ |